| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
|
N Engl J Med
|
2012
|
52.99
|
|
2
|
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.
|
N Engl J Med
|
2015
|
12.54
|
|
3
|
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.
|
J Clin Oncol
|
2014
|
9.86
|
|
4
|
Inhibition of the hedgehog pathway in advanced basal-cell carcinoma.
|
N Engl J Med
|
2009
|
8.55
|
|
5
|
Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors.
|
Clin Cancer Res
|
2011
|
4.05
|
|
6
|
Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599.
|
J Clin Oncol
|
2008
|
3.83
|
|
7
|
Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody.
|
Clin Cancer Res
|
2012
|
3.68
|
|
8
|
Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer.
|
J Clin Oncol
|
2008
|
2.59
|
|
9
|
Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer.
|
J Clin Oncol
|
2006
|
2.32
|
|
10
|
Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599.
|
J Clin Oncol
|
2010
|
1.93
|
|
11
|
Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity.
|
J Clin Oncol
|
2008
|
1.91
|
|
12
|
Delayed diagnosis and elevated mortality in an urban population with HIV and lung cancer: implications for patient care.
|
J Acquir Immune Defic Syndr
|
2006
|
1.66
|
|
13
|
Alterations of immune response of Non-Small Cell Lung Cancer with Azacytidine.
|
Oncotarget
|
2013
|
1.44
|
|
14
|
Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma.
|
J Clin Oncol
|
2012
|
1.37
|
|
15
|
Adjuvant treatment in non-small cell lung cancer: Where are we now?
|
J Natl Compr Canc Netw
|
2006
|
1.33
|
|
16
|
Comparative pharmacokinetics of weekly and every-three-weeks docetaxel.
|
Clin Cancer Res
|
2004
|
1.31
|
|
17
|
Antiangiogenic agents in combination with chemotherapy in patients with advanced non-small cell lung cancer.
|
Cancer Invest
|
2011
|
1.28
|
|
18
|
Asking the right questions: investigating needs assessments and health-related quality-of-life questionnaires for use in oncology clinical practice.
|
Support Care Cancer
|
2007
|
1.14
|
|
19
|
Prognostic models to predict survival in non-small-cell lung cancer patients treated with first-line paclitaxel and carboplatin with or without bevacizumab.
|
J Thorac Oncol
|
2012
|
1.09
|
|
20
|
Phase 2 study of pemetrexed and itraconazole as second-line therapy for metastatic nonsquamous non-small-cell lung cancer.
|
J Thorac Oncol
|
2013
|
1.05
|
|
21
|
Body mass index and its association with clinical outcomes for advanced non-small-cell lung cancer patients enrolled on Eastern Cooperative Oncology Group clinical trials.
|
J Thorac Oncol
|
2013
|
1.03
|
|
22
|
Harnessing the power of the immune system via blockade of PD-1 and PD-L1: a promising new anticancer strategy.
|
Immunotherapy
|
2014
|
1.02
|
|
23
|
Symptoms, supportive care needs, and function in cancer patients: how are they related?
|
Qual Life Res
|
2008
|
0.99
|
|
24
|
Needs assessments can identify scores on HRQOL questionnaires that represent problems for patients: an illustration with the Supportive Care Needs Survey and the QLQ-C30.
|
Qual Life Res
|
2010
|
0.97
|
|
25
|
Determination of the docetaxel vehicle, polysorbate 80, in patient samples by liquid chromatography-tandem mass spectrometry.
|
J Chromatogr B Analyt Technol Biomed Life Sci
|
2002
|
0.95
|
|
26
|
Phase I study of docosahexaenoic acid-paclitaxel: a taxane-fatty acid conjugate with a unique pharmacology and toxicity profile.
|
Clin Cancer Res
|
2003
|
0.94
|
|
27
|
Five National Cancer Institute-designated cancer centers' data collection on racial/ethnic minority participation in therapeutic trials: a current view and opportunities for improvement.
|
Cancer
|
2014
|
0.93
|
|
28
|
Randomized phase II study of pulse erlotinib before or after carboplatin and paclitaxel in current or former smokers with advanced non-small-cell lung cancer.
|
J Clin Oncol
|
2008
|
0.93
|
|
29
|
New strategies in lung cancer: translating immunotherapy into clinical practice.
|
Clin Cancer Res
|
2014
|
0.90
|
|
30
|
Chemotherapy for advanced stage non-small cell lung cancer.
|
Semin Thorac Cardiovasc Surg
|
2008
|
0.90
|
|
31
|
Bevacizumab maintenance in patients with advanced non-small-cell lung cancer, clinical patterns, and outcomes in the Eastern Cooperative Oncology Group 4599 Study: results of an exploratory analysis.
|
J Thorac Oncol
|
2012
|
0.89
|
|
32
|
Concordance of cancer patients' function, symptoms, and supportive care needs.
|
Qual Life Res
|
2009
|
0.89
|
|
33
|
"Who should receive epidermal growth factor receptor inhibitors for non-small cell lung cancer and when?".
|
Curr Treat Options Oncol
|
2007
|
0.89
|
|
34
|
Dual inhibition of the epidermal growth factor receptor pathway with cetuximab and erlotinib: a phase I study in patients with advanced solid malignancies.
|
Oncologist
|
2009
|
0.86
|
|
35
|
Systemic therapy, clinical outcomes, and overall survival in locally advanced or metastatic pulmonary carcinoid: a brief report.
|
J Thorac Oncol
|
2014
|
0.84
|
|
36
|
New strategies in lung cancer: epigenetic therapy for non-small cell lung cancer.
|
Clin Cancer Res
|
2014
|
0.81
|
|
37
|
What lies within: novel strategies in immunotherapy for non-small cell lung cancer.
|
Oncologist
|
2013
|
0.81
|
|
38
|
Adjuvant therapy for resected non-small-cell lung cancer: past, present, and future.
|
Curr Oncol Rep
|
2005
|
0.79
|
|
39
|
Targeting the immune system in the treatment of non-small-cell lung cancer.
|
Curr Treat Options Oncol
|
2013
|
0.79
|
|
40
|
Immune Checkpoint Therapy in Non-Small Cell Lung Cancer.
|
Cancer J
|
2016
|
0.77
|
|
41
|
Second-line Therapy for advanced non-small-cell lung cancer.
|
Curr Oncol Rep
|
2006
|
0.75
|
|
42
|
Optimizing the dose and schedule of anti-vascular endothelial growth factor antibodies in non-small-cell lung cancer.
|
Clin Lung Cancer
|
2008
|
0.75
|
|
43
|
Adjuvant therapy for resected non-small-cell lung cancer: recent advances, emerging agents, and lingering questions.
|
Curr Oncol Rep
|
2004
|
0.75
|
|
44
|
Cutaneous Eruptions in Patients Receiving Immune Checkpoint Blockade: Clinicopathologic Analysis of the Nonlichenoid Histologic Pattern.
|
Am J Surg Pathol
|
2017
|
0.75
|
|
45
|
Using Immune Checkpoint Inhibitors in Lung Cancer.
|
Oncology (Williston Park)
|
2016
|
0.75
|